[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Kull et al., 2013 - Google Patents

Force generation by kinesin and myosin cytoskeletal motor proteins

Kull et al., 2013

View HTML
Document ID
16934773973129740772
Author
Kull F
Endow S
Publication year
Publication venue
Journal of Cell Science

External Links

Snippet

Kinesins and myosins hydrolyze ATP, producing force that drives spindle assembly, vesicle transport and muscle contraction. How do motors do this? Here we discuss mechanisms of motor force transduction, based on their mechanochemical cycles and conformational …
Continue reading at pmc.ncbi.nlm.nih.gov (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
    • G06F19/16—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology for molecular structure, e.g. structure alignment, structural or functional relations, protein folding, domain topologies, drug targeting using structure data, involving two-dimensional or three-dimensional structures
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Similar Documents

Publication Publication Date Title
Kull et al. Force generation by kinesin and myosin cytoskeletal motor proteins
Ni et al. Emerging roles of allosteric modulators in the regulation of protein‐protein interactions (PPIs): A new paradigm for PPI drug discovery
Alhammad et al. The SARS-CoV-2 conserved macrodomain is a mono-ADP-ribosylhydrolase
Fallon et al. Structure of calmodulin bound to the hydrophobic IQ domain of the cardiac Cav1. 2 calcium channel
Johnson et al. A mechanism of calmodulin modulation of the human cardiac sodium channel
Rouka et al. Differential recognition preferences of the three Src homology 3 (SH3) domains from the adaptor CD2-associated protein (CD2AP) and direct association with Ras and Rab interactor 3 (RIN3)
Mao et al. Exploring protein structures by DNP-enhanced methyl solid-state NMR spectroscopy
Horsfall et al. Targeting PCNA with peptide mimetics for therapeutic purposes
Yan et al. Length-dependent motions of SARS-CoV-2 frameshifting RNA pseudoknot and alternative conformations suggest avenues for frameshifting suppression
Perez et al. Computational modeling as a tool to investigate PPI: From drug design to tissue engineering
Kawale et al. UvrD helicase–RNA polymerase interactions are governed by UvrD’s carboxy-terminal Tudor domain
Meller et al. Drug specificity and affinity are encoded in the probability of cryptic pocket opening in myosin motor domains
Douse et al. Targeting a dynamic protein–protein interaction: fragment screening against the malaria myosin A motor complex
Bodor et al. DYNLL2 dynein light chain binds to an extended linear motif of myosin 5a tail that has structural plasticity
Rouhana et al. Fragment-based identification of a locus in the Sec7 domain of Arno for the design of protein–protein interaction inhibitors
Fleming et al. Computation and mutagenesis suggest a right‐handed structure for the synaptobrevin transmembrane dimer
Benison et al. The interplay of ligand binding and quaternary structure in the diverse interactions of dynein light chain LC8
Espinoza‐Fonseca et al. Conformational changes of the p53‐binding cleft of MDM2 revealed by molecular dynamics simulations
Triveri et al. Protein allostery and ligand design: computational design meets experiments to discover novel chemical probes
Pineda-Sanabria et al. Versatile cardiac troponin chimera for muscle protein structural biology and drug discovery
Esposito et al. Divergent self-association properties of paralogous proteins TRIM2 and TRIM3 regulate their E3 ligase activity
Khayrutdinov et al. Structure of the Cdt1 C‐terminal domain: conservation of the winged helix fold in replication licensing factors
Zacharioudakis et al. Targeting protein conformations with small molecules to control protein complexes
Yokoyama et al. Structural and thermodynamic basis of the enhanced interaction between kinesin spindle protein Eg5 and STLC-type inhibitors
Khan et al. Probing structural changes among analogous inhibitor-bound forms of HIV-1 protease and a drug-resistant mutant in solution by nuclear magnetic resonance